PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-198505 |   Pharmaceuticals

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Proprotein Convertase Subtilisin/Kexin Type 9 Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET

7.1 GLOBAL PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 AFFiRiS AG

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Betagenon AB

16.3 Bioleaders Corp

16.4 BioLingus AG

16.5 Catabasis Pharmaceuticals Inc

16.6 Dicerna Pharmaceuticals Inc

16.7 Eli Lilly and Co

16.8 Ensemble Therapeutics Corp

16.9 Kowa Co Ltd

16.10 Novartis AG

16.11 Pfizer Inc

16.12 Regeneron Pharmaceuticals In

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Market by Type :

SX-PCK9
O-304
K-312
BLSM-201
DCRPCSK-9
Others

Market by Application :

Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others

Companies

AFFiRiS AG
Betagenon AB
Bioleaders Corp
BioLingus AG
Catabasis Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Ensemble Therapeutics Corp
Kowa Co Ltd
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals In

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.